Business
Polyrizon Targets $3.15B Epilepsy Market with Preclinical Studies for Innovative Rescue Treatment
Raanana, Israel, May 13, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “Polyrizon”), a development stage biotech company specializing in the development of innovative intranasal hydrogels, recently announced the initiation of preclinical studies for intranasal Benzodiazepines (BZDs), a first-line treatment for acute repetitive seizures (ARS) and status epilepticus, using its proprietary drug delivery platform. According to the World Health Organization (WHO), epilepsy
About this update from Polyrizon Ltd.
[{"type":"text","content":"Raanana, Israel, May 13, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “Polyrizon”), a development stage biotech company specializing in the development of innovative intranasal hydrogels, recently announced the initiation of preclinical studies for intranasal Benzodiazepines (BZDs), a first-line treatment for acute repetitive seizures (ARS) and status epilepticus, using its proprietary drug delivery platform.","length":440,"tagName":"p"},{"type":"text","content":"According to the World Health Organization (WHO), epilepsy is a neurological condition affecting about 50 million people worldwide. Many existing therapies fail to provide adequate control of acute repetitive seizures and may come with undesirable adverse effects. The global acute repetitive seizures market size was estimated at USD 3.15 billion in 2024 and is projected to grow at a CAGR of 12.7% from 2025 to 2030.","length":418,"tagName":"p"},{"type":"text","content":"The study will be conducted in collaboration with Professor Fabio Sonvico, Associate Professor at the Department of Food and Drug of the University of Parma (Italy) a leading expert in the development of intranasal and pulmonary drug delivery solutions and a member of the Company’s Scientific Advisory Board.","length":309,"tagName":"p"},{"type":"text","content":"These preclinical studies mark a step forward in evaluating Polyrizon’s Trap and Target™ (T&T) platform for the intranasal administration of Benzodiazepine, designed to enable rapid, targeted, and patient-friendly seizure rescue therapy.","length":241,"tagName":"p"},{"type":"text","content":"BZDs are well-established, first-line drugs for the acute treatment of seizures. They act by enhancing the inhibitory effects of gamma-aminobutyric acid (GABA) at the GABA-A receptor in the central nervous system, helping to quickly suppress seizure activity.","length":259,"tagName":"p"},{"type":"text","content":"Intranasal delivery of BZDs offers multiple advantages over traditional routes of administration, including ease of use and increased accessibility. This approach allows emergency responders, caregivers and at-risk individuals to administer life-saving medication rapidly and independently in out-of-hospital settings.","length":318,"tagName":"p"},{"type":"text","content":"“Launching this preclinical program marks an impo...